Drugs which antagonize 5-hydroxytryptamine and related indolealkylamines

  • Laszlo Gyermek
Part of the Handbook of Experimental Pharmacology/Handbuch der experimentellen Pharmakologie book series (HEP, volume 19)


Many concepts of drug antagonism in the last few decades have undergone significant change but certain principles of the subject are basically the same as laid down in the fundamental work of Clark published in 1937 on the pages of this handbook. The phenomenon of drug antagonism is certainly a complex one in which many factors participate. Its nature depends not only on the type of drug but more significantly on the biological system employed. In addition to the living substrate, the factors of its environment and time patterns are of major importance. Considering these factors the problem of drugs which antagonize 5-hydroxytryptamine (5-HT) and related indolealkylamines must also be realized as being rather complex. One escape from this problem would be to follow the trend of radical simplification which neglects most of the factors mentioned and deal with the drug-substrate complex on a purely mechanistic basis. This approach is certainly useful for the understanding of some basic underlying mechanisms which are biophysical and physicochemical in nature and are indeed more amenable to scientific analysis. Confronted, however, by a system such as the mammalian organism the solving of problems of drug antagonisms on a theoretical basis is nearly impossible. Accordingly, two trends of extremes are detected in the works published on this subject: First, the theoretical, with analyzing efforts, and a second, the practical aimed at data collecting. The first approach so far has not been able to develop new drugs, the second was often criticized as being nonscientific. The only possible way today is still to compromise and utilize both approaches. The information offered on these pages is a result of such a compromise utilizing the results of both types of research approaches.


Ergot Alkaloid Nictitate Membrane Stimulant Action Lysergic Acid Autonomic Ganglion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Abbott, K. H.: A new antiserotonin compound, UML-491 in the treatment of headache. Dis. nerv. Syst. 23, 579–583 (1962).PubMedGoogle Scholar
  2. [2]
    Adler, T. K., and A. Albert: The biological and physical properties of the azaindoles. J. Med. Chem. 6, 480–483 (1963).PubMedGoogle Scholar
  3. [3]
    Arnold, O. H., u. G. Hofman: Zur Psychopathologie des Dimethyl-traptamine. Wien. Z. Nervenheilk. 13, 438 (1957).PubMedGoogle Scholar
  4. [4]
    Axelrod, J.: The enzymatic N-methylation of serotonin and other amines. J. Pharmacol. exp. Ther. 138, 28–33 (1962).PubMedGoogle Scholar
  5. [5]
    Balestra, E. F.: Changes in (dermal reactions to) histamine and serotonin produced by various drugs. Sem. méd. 120, 498–500 (1962).Google Scholar
  6. [6]
    Barlow, R. B.: Effects on amine oxidase of substances which antagonize 5-hydroxytryptamine more than tryptamine on the rat fundus strip. Brit. J. Pharmacol. 16, 153–162 (1961).PubMedGoogle Scholar
  7. [7]
    Barlow, R. B., and I. Khan: Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparation. Brit. J. Pharmacol. 14, 99–107 (1959a).PubMedGoogle Scholar
  8. [8]
    Barlow, R. B., and I. Khan: Actions of some analogues of 5-hydroxytryptamine on the isolated rat uterus and the rat fundus strip preparations. Brit. J. Pharmacol. 14, 265–272 (1959b).PubMedGoogle Scholar
  9. [9]
    Barlow, R. B., and I. Khan: The use of the guinea-pig ileum preparation for the testing the activity of substances which imitate or antagonize the actions of 5-hydroxytrvptamine and tryptamine. Brit. J. Pharmacol. 14, 553–558 (1959).PubMedGoogle Scholar
  10. [10]
    Bartlet, A. L.: Some cocaine-like actions of 3-phenoxypropylguanide. Brit. J. Pharmacol. 18, 475–489 (1962).PubMedGoogle Scholar
  11. [11]
    Baruk, H., J. Launay Berges, and R. Perles: Action experimentale de la serotonine sur le comportement psychomoteur du Singe. Antagonisme et synergie avec les neuroleptiques et le L.S.D. 25. In: Henri Baruk and Jacques Launay (eds.). Annales Moreau de Tours, vol. I, Current memoires in psychopharmacology, p. 275–290. Paris: Presse Univ. France 1962.Google Scholar
  12. [12]
    Beach, V. L., and B. G. Steinetz: Quantitative measurement of Evans blue space in tissue of the rat; influence of 5-hydroxytryptamine antagonists and phenelzine on experimental inflammation. J. Pharmacol. exp. Ther. 131, 400–408 (1961).PubMedGoogle Scholar
  13. [13]
    Beleslin, D., and V. Varagić: The effect of noradrenaline on the blood pressure response to 5-hydroxytryptamine in rat. Arch. int. Pharmacodyn. 128, 100–111 (1960).Google Scholar
  14. [14]
    Beleslin, D., and V. Varagić: The effect of cooling and of 5-hydroxytryptamine on the peristaltic reflex of the isolated guinea pig ileum. Brit. J. Pharmacol. 13, 266–270 (1958).PubMedGoogle Scholar
  15. [15]
    Benassi, P.: Clinical experience with the pharmacodynamic action of BAS an antimetabolite of serotonin. [Ital.]Riv. sper. Freniat. 82, 266–270 (1958).Google Scholar
  16. [16]
    Benditt, E. P., and D.A. Rowley: Antagonism of 5-hydroxytryptamine by chlorpromazine. Science 123, 24 (1956).PubMedGoogle Scholar
  17. [17]
    Berde, B., W. Doepfner u. A. Cerletti: Über die Wirkungsdauer einiger Serotoninantagonisten. Helv. physiol. pharmacol. Acta 18, 537–544 (1956).Google Scholar
  18. [18]
    Berger, F. M., G. L. Campbell, C. D. Hendley, B. J. Lundwig, and T. D. Lynes: The action of transquilizers on brain potentials and serotonin. Ann. N.Y. Acad Sci. 66, 686–699 (1957).PubMedGoogle Scholar
  19. [19]
    Bergouignan, M., et A. Seilhean: La place des anti-serotonines dans le traitement des migraines et des cephalees vaso-motorices. Presse méd. 68, 2176–2178 (1960).Google Scholar
  20. [20]
    Bertaccint, G., and P. Zamboni: The relative potency of 5-hydroxytryptamine like substances. Arch. int. Pharmacodyn. 133, 138–156 (1961).Google Scholar
  21. [21]
    Bevan, J. A., and M. Verity: Action of lobeline on intrathoracic receptors: a comparison with phenyldiguanide, serotonin and veratridine. J. Pharmacol. exp. Ther. 132, 42–49 (1961).Google Scholar
  22. [22]
    Bhattacharya, B. K.: A pharmacological study on the effect of 5-hydroxytryptamine and its antagonists on the bronchial musculature. Arch. int. Pharmacodyn. 103, 357–369 (1955).PubMedGoogle Scholar
  23. [23]
    Bindler, E., and L. Gyermek: Influence of 5-HT antagonists on the ganglionic stimulant action of 5-HT and DMPP. Fed. Proc. 20, 319 (1961).Google Scholar
  24. [24]
    Bock, K. H., H. Dengler, H. M. Kuhn u. K. Matthes: Die Wirkung von 5-hydroxytryptamin auf Blutdruck, Haut-und Muskeldurchblutung des Menschen. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 230, 257–273 (1957).Google Scholar
  25. [25]
    Bodi, T., P. E. Siegler, M. Gerschenfeld, E. B. Brown, and J. H. Nodine: Clinical evaluation of a new antihistamin (cyproheptadine). Fed. Proc. 19, 195 (1960).Google Scholar
  26. [26]
    Bradley, P. B., and A. J. Hance: The effects of intraventricular injections of d-LSD and 5-hydroxytryptamine on the electrical activity of the brain of the conscious cat. J. Physiol. (Lond.) 132, 50 (1956).Google Scholar
  27. [27]
    Bradley, P. B., and B. J. Key: A comparative study on the effects of drugs on the arousal system of the brain. Brit. J. Pharmacol. 14, 340–349 (1959).PubMedGoogle Scholar
  28. [28]
    Brodey, J. F., W.M.G. Steiner, and Harold E. Himwich: An electrographic study of psilocin and 4-methyl-alpha-methyltryptamine (MP-809-Sandoz). J. Pharmacol. exp. Ther. 140, 8–18 (1963).PubMedGoogle Scholar
  29. [29]
    Brodie, B. B., and P. A. Shore: A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann. N.Y. Acad. Sci. 66, 631–642 (1957).PubMedGoogle Scholar
  30. [30]
    Brown, B. B.: Lysergic acid diethylamide antagonism of certain drugs. Ann. N.Y. Acad. Sci. 66, 677–685 (1957).PubMedGoogle Scholar
  31. [31]
    Brownlee, G., and E. S. Johnson: The site of the 5-hydroxytryptamine receptors on the intramural nervous plexus of the guinea pig isolated ileum. Brit. J. Pharmacol. 21, 306–322 (1963).PubMedGoogle Scholar
  32. [32]
    Buchel, L., J. Levy, and O. Tanguy: Influence of serotonin and dl-5-hydroxytryptophane upon experimental sleep with or without iproniazid. Agressologie 1, 389–396 (1960) [French].Google Scholar
  33. [33]
    Bulle, P. H.: Effects of reserpine and chlorpromazine in prevention of cerebral edema and reversible cell damage. Proc. Soc. exp. Biol. (N.Y.) 94, 553–556 (1957).Google Scholar
  34. [34]
    Buñag, R. D., and E. J. Walaszek: Differential antagonism by BAS-phenol (1-benzyl-2-methyl-5-hydroxytryptamine) of responses to the indolealkylamines. J. Pharmacol. exp. Ther. 136, 59–67 (1962).PubMedGoogle Scholar
  35. [35]
    Buñag, R. D., and E. J. Walaszek: Blockade of depressor responses to serotonin and tryptamine by lysergic acid derivatives in the chicken. Arch. int. Pharmacodyn. 135, 142–151 (1962).PubMedGoogle Scholar
  36. [36]
    Buñag, R. D., and E. J. Walaszek: The latent vasopressor effect of serotonin in the chicken. Arch. int. Pharmacodyn. 143, 108–118 (1963).PubMedGoogle Scholar
  37. [37]
    Buscaino, G. A.: Serotonin and psychiatry. Symposium IVth Giornata della Settimana Medica Fiorentina 1960, p. 123–150.Google Scholar
  38. [38]
    Cahen, R., J. Nadaud, and S. Aubron: New antagonists of 5-hydroxytryptamine (HT). Biochem. Pharmacol. 8, 1, 34 (1961).Google Scholar
  39. [39]
    Cahen, R., M. Sautai, D. Bonnet, and F. Bouche: Pharmacology of p-chloro-alpha-(2-dimethylaminoethoxy) benzylpyridine. II. Peripheral anti-serotonin activity. Ann. pharm. franç. 21, 123–131 (1963).PubMedGoogle Scholar
  40. [40]
    Cahn, J., G. Georges et R. Pierre: Essais d’anesthésie prolongée par la 5-hydroxytryptamine (séronine) et contrôlée par des drouges à action neurovégétative. II. Etude chez. le rat. C. R. Soc. Biol. (Paris) 150, 162–164 (1956).Google Scholar
  41. [41]
    Calì, G., and C. Cordova: Influences of synthetic antihistamines on the rate of gastric secretion by 5-hydroxytryptamine. [Ital.] Rass. Fisiopat. clin. ter. 28, 1072–1085 (1956).Google Scholar
  42. [42]
    Cambridge, G. W., and A. J. Holgate: Superfusion as a method for the study of drug antagonism. Brit. J. Pharmacol. 10, 326–335 (1955).PubMedGoogle Scholar
  43. [43]
    Canal, N., and A. Ornesi: Serotonin as a hyperthermal agent. Atti Accad. med. lombarda 16, 64–69 (1961).Google Scholar
  44. [44]
    Casentini, S., and G. Galli: Serotonin and antiserotonins and gastric motility. Boll. Soc. ital. Biol. sper. 32, 1640–1642 (1956).PubMedGoogle Scholar
  45. [45]
    Cato, J., and E. J. Cafruny: Effects of tetrazotized diorthoanisidine on depressor response to 5-hydroxytryptamine in the rabbit. Proc. Soc. exp. Biol. (N.Y.) 104, 103–105 (1960).Google Scholar
  46. [46]
    Cerletti, A.: Pharmacology of psilocybin. Proc. intern. Congr. Neuro-Pharm. 1st Rome 1959, p. 291–294.Google Scholar
  47. [47]
    Cerletti, A., u. B. Berde: Die Wirkung von d-Lysergsäure-diäthylamid (LSD-25) and 5-Oxytryptamin auf die Chromatophoren von Poecilia reticulatus. Experientia (Basel) 11, 312–313 (1955).Google Scholar
  48. [48]
    Cerletti, A., and W. Doepfner: Comparative study on the serotonin antagonism of hydrazides of lysergic acid and of ergot alkaloids. J. Pharmacol. exp. Ther. 122, 124–136 (1958).PubMedGoogle Scholar
  49. [49]
    Cerletti, A., u. H. Konzett: Spezifische Hemmung von 5-Oxytryptamin-Effekten durch Lysergsäurediäthylamid und ähnliche Körper. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 228, 146–148 (1956).Google Scholar
  50. [50]
    Cerletti, A., and E. Rothlin: Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature (Lond.) 176, 785–786 (1955).Google Scholar
  51. [51]
    Cerletti, A., u. H. Weidmann: Untersuchungen zur Differenzierung des vasokonstriktorischen Effektes von Serotonin. Arch. int. Pharmacodyn. 139, 177–186 (1962).PubMedGoogle Scholar
  52. [52]
    Chessin, M., E. R. Kramer, and C. C. Scott: Modification of the pharmacology of reserpine and serotonin by iproniazid. J. Pharmacol. exp. Ther. 119, 453–460 (1957).PubMedGoogle Scholar
  53. [53]
    Chodera, A.: Anti-serotonin compounds. Polski Tyg. lek. 17, 1797–1800 (1962).Google Scholar
  54. [54]
    Chodera, A.: Blockade of 5-hydroxytryptamine antidiuresis in rats by 2-bromolysergic acid diethylamide tartrate and 1-methyl-lysergic acid butanol-amide. J. Pharm. Pharmacol. 15, 386–389 (1963).PubMedGoogle Scholar
  55. [55]
    Cima, G., and C. Freschi: Action of serotonin and its antagonists on the isolated uterus (Ital.) Boll. Soc. ital. Biol. sper. 33, 867–869 (1957).PubMedGoogle Scholar
  56. [56]
    Clark, A. J.: General pharmacology, vol. 4 of HEFFTER, HEUBNER and SCHüLLER, Handbuch der experimentellen Pharmakologie. Berlin: Springer 1937.Google Scholar
  57. [57]
    Cleugh, J., J. H. Gaddum, P. Holton, and E. Leach: Essay of substance P on the fowl rectal caecum. Brit. J. Pharmacol. 17, 144–158 (1961).PubMedGoogle Scholar
  58. [58]
    Cole, J. W., and G. G. Bertino: Effect of chlorpromazine on excretion of 5-hydroxyindoleacetic acid in a patient with malignant carcinoid. Proc. Soc. exp. Biol. (N.Y.) 93, 100–102 (1956).Google Scholar
  59. [59]
    Comroe Jr., J. H., B. Van Linger, R, C. Stroud, and A. Roncoroni: Reflex and direct cardiopulmonary effects of 5-OH-5-tryptamine (serotonin) their possible role in pulmonary embolism and coronary thrombosis. J. Physiol. (Lond.) 173, 379–386 (1953).Google Scholar
  60. [60]
    Cook, L., and E. Weidley: Behavioral effects of some psvchopharmacological agents. Ann. N.Y. Acad. Sci. 66, 740–752 (1957).PubMedGoogle Scholar
  61. [61]
    Corne, S. J., R. W. Pickering, and B. T. Warner: A method for assessing the effects of drugs on the central actions of 5-hvdroxytryptamine. Brit. J. Pharmacol. 20, 106–120 (1963).PubMedGoogle Scholar
  62. [62]
    Costa, E.: Effects of hallucinogenic and tranquillizing drugs on serotonin evoked uterine contractions. Proc. soc. exp. Biol. (N.Y.) 91, 39–41 (1956).Google Scholar
  63. [63]
    Costa, E., G. L. Gessa, C.W. Hirsch, R. Kiintzman, and B.B. Brodie: On current status of serotonin as a brain neurohormone and on action of reserpine-like drugs. Ann. N.Y. Acad. Sci. 96, 118–130 (1942).Google Scholar
  64. [64]
    Costa, E., and F. Rinaldi: Biochemical and EEG changes in the brain of rabbits injected with 5-hvdroxvtrvptophane (influence of chlorpromazine premedication). Amer. J. Physiol. 194, 214–220 (1958).PubMedGoogle Scholar
  65. [65]
    Courvoisier, S., R. Ducrot et L. Lulou: Nouveaux aspects expérimentaux de l’activité central des dérives de la phénothiazine. Psychotropic drugs ed. by S. Garattini and V. Ghetti, p. 373–391. Amsterdam: Elsevier Publ. Co. 1957.Google Scholar
  66. [66]
    Courvoisier, S., R. Ducrot et L. Lulou., et O. Leau: Propriétés pharmacologiques générales d’un nouveau dérive de la phénothiazine doué d’activité antihistaminique et antiallergique puissante. la dioxo-9-(dimethvlamino-3′-methyl-2′-propyl)-10-phenothiazine. Arch. int. Pharmacodyn. 135, 364–375 (1962).PubMedGoogle Scholar
  67. [67]
    Craps, L., and TH. Inderbitzin: Anaphylactoid and anaphylactic cutaneous exoserosis in the rat. Int. Arch. Allergy 18, 268–285 (1961).PubMedGoogle Scholar
  68. [68]
    Crossland, J.: Chemical transmission in the central nervous system. J. Parm. Pharmacol. 12, 1–36 (1960).Google Scholar
  69. [69]
    Curtis, D. R.: Action of 3-hydroxytyramine and some tryptamine derivatives on spinal neurones. Nature (Lond.) 194, 292 (1962).Google Scholar
  70. [70]
    Curtis, D. R., and R. Davis: Pharmacological studies upon neurones of the lateral geniculate nucleus of the cat. Brit. J. Pharmacol. 18, 217–246 (1962).PubMedGoogle Scholar
  71. [71]
    Curtis, D. R., and K. Koizumi: Chemical transmitter substances in the brain stem of the cat. J. Neurophysiol. 24, 80–90 (1961).PubMedGoogle Scholar
  72. [72]
    Dalessio, D. J.: Migraine headache. Serotonin and serotonin antagonism. J. Amer. med Ass. 181, 318–321 (1962).Google Scholar
  73. [73]
    Dasgupta, S. R.: Effect of chlorpromazine on antidiuresis provoked by 5-hydroxytryptamine. Arch. int. Pharmacodyn. 112, 264–271 (1957).PubMedGoogle Scholar
  74. [74]
    Day, M., and J. R. Vane: An analysis of the direct and indirect actions of drugs on the isolated guinea pig ileum. Brit. J. Pharmacol. 20, 150–170 (1963).PubMedGoogle Scholar
  75. [75]
    De Baran, L., G. Gogolak, V. G. Longo, and CH. Stumpf: Action of tryptamine on the electrical activity of single hippocampal neurons. J. Pharmacol. exp. Ther. 139, 337–344 (1963).Google Scholar
  76. [76]
    De Caro, G.: Antagonistic action of several lysergic acid derivatives on antidiuresis induced by 5-hydroxytryptamine. Arch. int. Pharmacodyn. 14, 54–61 (1963).Google Scholar
  77. [77]
    Del Greco, F., G. M. C. Masson, and A. C. Corcoran: Renal and arterial effects of serotonin in the anesthetized rat. Amer. J. Physiol. 187, 509–514 (1956).Google Scholar
  78. [78]
    Delay, J., et J. Thuillier: Dualité d’action du diéthylamide de l’acide lysergique sur la contraction utérine provoqueé par la 5-hydroxvtrvptamine (serotonine). C. R. Soc. biol. (Paris) 150, 1335–1336 (1956).Google Scholar
  79. [79]
    Doepfner, W., u. A. Cerletti: Über den Serotonin-Antagonismus einiger Antihistaminika unter Berücksichtigung ihrer chemischen Struktur. Int. Arch. Allergy 10, 348–354 (1957).PubMedGoogle Scholar
  80. [80]
    Doepfner, W., u. A. Cerletti: Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat’s paw by serotonin. Int. Arch. Allergy 12, 89–97 (1958).PubMedGoogle Scholar
  81. [81]
    Domenjoz, R., and W. Theobald: Pharmakologie des Tofranil (N-(3-Dimethyl-aminopropyl)-iminodibenzyl-Hydrochlorid). Arch. int. Pharmacodyn. 120, 450–488 (1959).PubMedGoogle Scholar
  82. [82]
    Domer, F. R., and V. G. Longo: Effect of 5-hydroxytryptophan on the cerebral electrical activity of the rabbit, Arch. int. Pharmacodyn. 136, 204–218 (1962).Google Scholar
  83. [83]
    Dominguez-Lazaro, A. R., A. Sastre-Castillo, J. Perez-Guerrero, and J. L. Calleja-Canelas: UML-491 (1-methyl-D-lysergic acid butanolamide) in the prevention and treatment of migraine and other tvpes of headaches. Rev. clin. esp. 87, 273–277 (1962).PubMedGoogle Scholar
  84. [84]
    Eble, J. N.: An analysis of the reversal of the tryptamine depressor effect in the chicken by diphenhydramine and tranylcypromine. J. Pharmacol. exp. Ther. 140, 243–248 (1963).Google Scholar
  85. [85]
    Ehrhart, G., and I. Henning: 1-Benzylgramine derivatives with serotonin antagonism. Arch. Pharm. 294, 550–555 (1961).PubMedGoogle Scholar
  86. [86]
    Erspamer, V.: Observations on alleged serotonin-(enteramine)-like nature of cerebral pressor substance of TAYLOR, PAGE and COCORAN. Arch. intern. Med. 90, 505–512 (1952).Google Scholar
  87. [87]
    Erspamer, V.: Modification of the actions of enteramine by sympathomimetic and sympatholytic agents. Rie. Sci. 22, 694–702 (1952).Google Scholar
  88. [88]
    Erspamer, V.: The enteramine-like action of certain indolealkylamines, 2-methyl-3-ethyl-5-aminoindole and of alkaloids of the harmine group. Ric. Sci. 23, 1203–1207 (1953).Google Scholar
  89. [89]
    Erspamer, V.: Pharmacological studies on enteramine (5-hydroxytryptamine). IX. Influences of sympathomimetic and sympatholytic drugs on the physiological and pharmacological actions of enteramine. Arch. int. Pharmacodyn. 93, 293–316 (1953).PubMedGoogle Scholar
  90. [90]
    Erspamer, V.: Gramme derivatives antagonistic to 5-hydroxytryptamine. Science 121, 369–370 (1955).PubMedGoogle Scholar
  91. [91]
    Fanchamps, A., W. Doepfner, H. Weidmann u. A. Cerletti: Pharmakologische Charakterisierung von Deseril, einem Serotonin-Antagonisten. Schweiz. med. Wschr. 90, 1040–1046 (1960).PubMedGoogle Scholar
  92. [92]
    Fastier, F. N.: Structure activity relationships of amidine derivatives. Pharmacol. Rev. 14, 37–90 (1962).PubMedGoogle Scholar
  93. [93]
    Erspamer, V., M. A. Mcdowell, and H. Waal: Pharmacological properties of phenyldiguanide and other amidine derivatives in relation to those of 5-hydroxytryptamine. Brit. J. Pharmacol. 14, 527–535 (1959).Google Scholar
  94. [94]
    Ferguson, J.: Action of serotonin on motility of aneural smooth muscle. Fed. Proc. 16, 37 (1957).Google Scholar
  95. [95]
    Fingl, E., and J. H. Gaddxjm: Hydroxytryptamine blockade by dihydroergotamine in vitro. Fed. Proc. 12, 320 (1953).Google Scholar
  96. [96]
    Fink, M. A.: Anaphylaxis in the mouse: Possible relation of the Schultz-Dale reaction to serotonin release. Proc. Soc. exp. Biol. (N.Y.) 92, 673–675 (1956).Google Scholar
  97. [97]
    Flückiger, E., and R. Salzmann: Serotoninantagonismus an der Placenta. Experientia (Basel) 17, 131 (1961).Google Scholar
  98. [98]
    Frahm, M.: Beeinflussung der Meerschweinchenatmung durch 5-Hydroxytryptamine. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 232, 286–287 (1957).Google Scholar
  99. [99]
    Franchlmont, P., H. Van Cauwenberg, and J. Lecomte: Action of serotonin and one of its inhibitors (UML-491) on development of granulation tissue reactions in the rat. C. R. Soc. Biol. (Paris) 155, 432–435 (1961).Google Scholar
  100. [100]
    Franchlmont, P., J. Lecomte, and H. Van Cauwenberg: Influence of serotonin and one of its antagonists on development of local edematous reactions provoked by various agents in the rat. C. R. Soc. Biol. (Paris) 155, 180–184 (1961).Google Scholar
  101. [101]
    Franco-Browders, S., G. M. S. Masson, and A. C. Corcoran: PHARMACOLOGIC characterization of reserpine responses in rats treated with Iproniazid. Proc. Soc. exp. Biol. (N.Y.) 97, 778–780 (1958).Google Scholar
  102. [102]
    Freyburger, W. A., B. E. Graham, M. M. Rapport, P. H. Seay, W. M. Govier, O. F. Swoap, and M. J. VAN DER Brook: The pharmacology of 5-hydroxy tryptamine (Serotonin). J. Pharmacol. exp. Ther. 105, 80–86 (1952).PubMedGoogle Scholar
  103. [103]
    Fu, CH. CH., and Hsu, CH. T.: Studies on the tranquilizing effect of methyltryptamine. Tai-wan-i-hsueh-hui tsa-chih. 59, 296–301 (1960).Google Scholar
  104. [104]
    Furchgott, R. F.: Dibenamine blockade in strips of rabbit aorta and its use in differentiating receptors. J. Pharmacol. exp. Ther. 111, 265–284 (1955).Google Scholar
  105. [105]
    Gaddum, J. H.: Antagonism between LSD and 5-hydroxytryptamine. J. Physiol. (Lond.) 121, 15 (1953).Google Scholar
  106. [106]
    Gaddum, J. H.: Tryptamine receptors. J. Physiol. (Lond.) 119, 363–368 (1953).Google Scholar
  107. [107]
    Gaddum, J. H.: Drugs antagonistic to 5-hydroxytryptamine. In: Ciba Symposium on Hypertension, p. 75–77. London: Churchill Ltd. 1954.Google Scholar
  108. [108]
    Gaddum, J. H.: Serotonin LSD interactions. Ann. N.Y. Acad. Sci. 66, 643–648 (1957a).PubMedGoogle Scholar
  109. [109]
    Gaddum, J. H.: Drugs which antagonize the actions of 5-hydroxytryptamine on peripheral tissues. In: 5-hydroxytryptamine, ed. by G.P. Lewis, p. 195–205. New York: Pergamon Press 1957b.Google Scholar
  110. [110]
    Gaddum, J. H., and K. A. Hameed: Drugs which antagonize 5-hydroxytryptamine. Brit. J. Pharmacol. 9, 240–248 (1954).PubMedGoogle Scholar
  111. [111]
    Gaddum, J. H., and K. A. Hameed., D. E. Hathaway, and F. F. Stephens: Quantitative studies of antagonists for 5-hydroxytryptamine. Quart. J. exp. Physiol. 40, 49–74 (1955).PubMedGoogle Scholar
  112. [112]
    Gaddum, J. H., C. O. Hebb, A. Silver, and A. A. B. Swan: 5-Hydroxytryptamine. Pharmacological action and destruction in perfused lungs. Quart. J. exp. Physiol. 38, 255–262 (1953).PubMedGoogle Scholar
  113. [113]
    Gaddum, J. H., and M. K. Paasoken: The use of some Molluscan hearts for the estimation of 5-hydroxytryptamine. Brit. J. Pharmacol. 10, 474–483 (1955).PubMedGoogle Scholar
  114. [114]
    Gaddum, J. H., and Z. P. Picarelli: TWO kinds of tryptamine receptor. Brit. J. Pharmacol. 12, 323–328 (1957).PubMedGoogle Scholar
  115. [115]
    Gaddum, J. H., and J. C. Szerb: Essay of substance P on goldfish intestine in a microbath. Brit. J. Pharmacol. 7, 451–463 (1961).Google Scholar
  116. [116]
    Gaddum, J. H., and M. Vogt: Some central actions of 5-hydroxytryptamine, tryptamine and various antagonists. Brit. J. Pharmacol. 11, 175–179 (1956).PubMedGoogle Scholar
  117. [117]
    Gallant, D.M., M. P. Bishop, C. A. Steele, and C. D. Noblin: The relationship between serotonin antagonism and tranquilizing activity. Amer. J. Psychiat. 119, 882 (1963).PubMedGoogle Scholar
  118. [118]
    Ganley, O. H.: Protective effect of cyproheptadine, a new antihistamine antiserotonin compound on lethal burns in the mouse. Arch. int. Pharmacodyn. 138, 125–132 (1962).PubMedGoogle Scholar
  119. [119]
    Garattini, S., and L. Valzelli: Antagonism of serotonin by chlorpromazine from one side and by reserpine on the other (Ital.). Boll. Soc. ital. Biol. sper. 31, 1648–1652 (1955).PubMedGoogle Scholar
  120. [120]
    Garattini, S., and L. Valzelli: Substances interfering with the narcosis-potentiating activity of serotonin (Ital.). Boll. Soc. ital. Biol. sper. 32, 292–295 (1956a).PubMedGoogle Scholar
  121. [121a]
    Garattini, S., and L. Valzelli: Substances interfering with the antidiuretic action of serotonin (Ital.). Boll. Soc. ital. Biol. sper. 32, 295–299 (1956b).PubMedGoogle Scholar
  122. [121]
    Garyen, J. D.: Pharmacological blocking actions of atropine and certain atropine-like compounds. J. Pharm. Pharmacol. 8, 256–263 (1956).Google Scholar
  123. [122]
    Gelfand, M. D., and G. B. West: Hydroxybutypropylamide and hvdroxylamide of 1-methyllysergic acid. Int. Arch. Allergy 18, 286–291 (1961).PubMedGoogle Scholar
  124. [123]
    Gessner, P. K., W. M. Mcisaac, and I. H. Page: Pharmacological actions of some methoxyindolealkylamines. Nature (Lond.) 190, 179–180 (1961).Google Scholar
  125. [124]
    Gessner, P. K., and I. H. Page: Behavioral effects of 5-methoxy-N, N-dimethyltryptamine and other tryptamines and lysergic acid diethylamide (LSD-25). Amer. J. Physiol. 203, 167–172 (1962).Google Scholar
  126. [125]
    Gey, K. F., and A. Pletscher: Influence of chlorpromazine and chlorprothixene on cerebral metabolism of 5-hydroxytryptamine, noradrenaline, and dopamine. J. Pharmacol. exp. Ther. 133, 18–24 (1961).PubMedGoogle Scholar
  127. [126]
    Gião, J. M., and T. Rico: Action of some phenothiazine derivatives on the edema provoked by serotonin in the rat. C. R. Acad. Sci. (Paris) 156, 207–209 (1962).Google Scholar
  128. [126a]
    Ginzel, K. H.: Die Wirkung von 5-OH Tryptaminen und Antagonisten auf das peristaltische Reflex. Naunyn-Schmiedebergs Arch. exp. Path Pharmak. 232, 287–288 (1957).Google Scholar
  129. [127]
    Ginzel, K. H., and S. R. Kottegoda: A study of the vascular actions of 5-hydrcxytryptamine, tryptamine, adrenaline, and nor-adrenaline. Quart. J. exp. Physiol. 38, 225–231 (1953).PubMedGoogle Scholar
  130. [128]
    Gogerty, J. H., and J. M. Dille: Pharmacology of d-lysergic acid morpholide (LSM). J. Pharmacol. exp. Ther. 120, 340–348 (1957).PubMedGoogle Scholar
  131. [129]
    Gözsy, B., and L. Kátó: Factors other than histamine affecting capillary permeability. Int. Arch. Allergy 19, 168–177 (1961).PubMedGoogle Scholar
  132. [130]
    Greeff, K., B. G. Benfey u. A. Bokelmann: Anaphylaktische Reaktionen am isolierten Herzvorhofpräparat des Meerschweinchens und ihre Beeinflussung durch Antihistaminica, B.O.L., Dihydroergotamine und Reserpin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 236, 421–434 (1959).Google Scholar
  133. [131]
    Greenberg, M. J.: The responses of the venus heart to catechol amines and high concentrations of 5-hydroxytryptamine. Brit. J. Pharmacol. 15, 365–374 (1960a).PubMedGoogle Scholar
  134. [132]
    Greenberg, M. J.: Structure activity relationship of tryptamine analogues on the heart of venus mercenaria. Brit. J. Pharmacol. 15, 375–388 (1960b).PubMedGoogle Scholar
  135. [133]
    Grette, K.: Determination of 5-hydroxytryptamine on the isolated, perfused pig ear. Acta pharmacol. (Kbh.) 13, 177–183 (1957).Google Scholar
  136. [134]
    Gryglewski, R.: The antiserotonin properties of γ-aminobutyrylcholine. Bull. Acad. pol. Sci., Ser. Sci. Biol. II, 51–52 (1963).Google Scholar
  137. [134a]
    Gunn, C. G.: Some CNS electrophysiologic effects of serotonin and lysergic acid diethylamide. Psychiat. Res. Rep. Amer. psychiat. Ass. 12, 194–203 (1960).PubMedGoogle Scholar
  138. [135]
    Guth, P. S., and M. A. Spirtes: Interaction in the central nervous system between serotonin and lysergic acid derivatives. Proc. intern. Congr. Neuro-Pharm. Ist, Rome 1958, p. 319–323 (1959).Google Scholar
  139. [136]
    Gyermek, L.: Beiträge zur Pharmakologie vom Tryptamin, Tyramin und Phenyl-ethylamin. Acta physiol. Acad. Sci. hung. 4, 323–332 (1953).Google Scholar
  140. [137]
    Gyermek, L.: Chlorpromazine: A serotonin antagonist? Lancet 1955 II, 274.Google Scholar
  141. [138]
    Gyermek, L.: The action of 5-hydroxytryptamine on the urinary bladder of the dog. Pharmacologist 2, 89 (1960).Google Scholar
  142. [139]
    Gyermek, L.: 5-Hydroxytryptamine antagonists. Pharmacol. Rev. 13, 399–439 (1961).PubMedGoogle Scholar
  143. [140]
    Gyermek, L.: 5-Hydroxy-3-indoleacetamidine: a new type of blocking agent against 5-hydroxytryptamine. Nature (Lond.) 192, 465 (1961b).Google Scholar
  144. [141]
    Gyermek, L.: Action of 5-hydroxytryptamine on the urinary bladder of the dog. Arch. int. Pharmacodyn. 137, 137–144 (1962b).PubMedGoogle Scholar
  145. [142]
    Gyermek, L.: Antagonists of 5-hydroxytryptamine. Proceedings of the I.U.P.S. XXII. Int. Congr., Leiden 1962b. Excerpta med. (Amst.) I/1, 28–36 (1962).Google Scholar
  146. [143]
    Gyermek, L.: A new class of 5-hydroxytryptamine antagonists. J. Med. Chem. 7, 280–284 (1964a).PubMedGoogle Scholar
  147. [144]
    Gyermek, L.: Action of guanidme derivatives on autonomie ganglia. Arch. int. Pharmacodyn. 150, 570–581 (1964b).PubMedGoogle Scholar
  148. [145]
    Gyermek, L.: Unpublished observations (1964c).Google Scholar
  149. [146]
    Gyermek, L., and E. Bindler: Blockade of the ganglionic stimulant action of 5-hvdroxytryptamine. J. Pharmacol. exp. Ther. 135, 344–348 (1962a).PubMedGoogle Scholar
  150. [147]
    Gyermek, L., and E. Bindler: Action of indole alkylamines and amidines on the inferior mesenteric ganglion of the cat. J. Pharmacol. exp. Ther. 138, 159–164 (1962b).PubMedGoogle Scholar
  151. [148]
    Gyermek, L., and E. Bindler., and L. Soffer: Ganglionic stimulation by ω-N-methyl derivatives of 5-hydroxytryptamine (5-HT). Fed. Proc. 21, 335 (1962).Google Scholar
  152. [149]
    Gyermek, L., G. Lazar, and Z. Csak: The antiserotonin action of chlorpromazine and some other phenothiazine derivatives. Arch. int. Pharmacodyn. 107, 62–74 (1956).PubMedGoogle Scholar
  153. [150]
    Gyermek, L., and K. Nádor: The pharmacology of tropane compounds in relation of their steric structure. J. Pharm. Pharmacol. 9, 209 (1957).PubMedGoogle Scholar
  154. [151]
    Gyermek, L., and C. Possemato: Potentiation of 5-hydroxytryptamine by imipramine. Med. exp. (Basel) 3, 225–229 (1960).Google Scholar
  155. [152]
    Gyermek, L., and T. Sumi: Potentiating actions of indolealkylamines and lysergic acid diethylamide on reflexes elicited by 5-hydroxytryptamine. Proc. Soc. exp. Biol. (N.Y.) 114, 436–439 (1963).Google Scholar
  156. [153]
    Halbert, S. A., R. Bircher, and E. Dahl: Studies on the mechanism of the lethal toxic action of streptolysin “O” and the protection by certain antiserotonin drugs. J. Lab. clin. Med. 61, 437–452 (1963).PubMedGoogle Scholar
  157. [154]
    Haley, T. J.: 5-Hydroxytryptamine antagonism by LSD after intracerebral injection in conscious mice. J. Amer. pharm. Ass., sci. Ed. 46, 428–430 (1957).Google Scholar
  158. [155]
    Haley, T. J. A. M. Flesher, K. Raymond, N. Komesu, and P. Williams: A pharmacologie study of Mellaril, 2-methyl-mercapto 10-(2-(N-methyl-2-piperidyl)-ethyl) phenothiazine HC1. Toxicol. appl. Pharmacol. 1, 377–383 (1959).Google Scholar
  159. [156]
    Halpern, B. N., P. Liacopoulos et M. Liacopoulos-Briot: Recherches sur les substances exogènes et endogènes agissant sur la permeabilité capillaire et leur antagonistes. Arch. int. Pharmacodyn. 119, 56–101 (1959).PubMedGoogle Scholar
  160. [157]
    Halpern, B. N., T. Neveu, and S. Spector: On the nature of the chemical mediators involved in anaphylactic reactions in mice. Brit. J. Pharmacol. 20, 389–398 (1963).PubMedGoogle Scholar
  161. [158]
    Hance, A. J., and P. B. Bradley: The effect of intraventricular injections of drugs on the electrical activity of the brain of the conscious cat. Abstr. XXth Int. Physiol. Congr. p. 391–393, Brussels 1956.Google Scholar
  162. [159]
    Harris, L. S., and F. L. Uhle: Four substituted indoles as antagonists to 5-hydroxytryptamine and to the veratrine response. J. Pharmacol. exp. Ther. 128, 358–262 (1960).PubMedGoogle Scholar
  163. [160]
    Harry, J.: The action of drugs on the circular muscle strip from the guinea pig isolated ileum. Brit. J. Pharmacol. 20, 399–417 (1963).PubMedGoogle Scholar
  164. [161]
    Hertzler, E. C.: 5-hydroxytryptamine and transmission in sympathetic ganglia. Brit. J. Pharmacol. 17, 406–413 (1961).PubMedGoogle Scholar
  165. [162]
    Herxheimer, H.: The 5-hydroxytryptamine shock in the guinea pig. J. Physiol. (Lond.) 128, 435 (1955).Google Scholar
  166. [163]
    Herxheimer, H.: Bronchoconstrictor agents and their antagonists in the intact guinea pig. Arch. int. Pharmacodyn. 106, 371–380 (1956).PubMedGoogle Scholar
  167. [164]
    Higginbotham, R. D.: Influence of adrenalectomy and cortisol on resistance of mice to histamine, serotonin, anaphylactic and endotoxin shocks. J. Allergy 33, 35–44 (1962).PubMedGoogle Scholar
  168. [165]
    Hobbiger, F.: Antagonism by aminobutyric acid to the actions of 5-hydroxy-tryptamine and nicotine on isolated organs. J. Physiol. (Lond.) 144, 349–360 (1958).Google Scholar
  169. [165a]
    Hoffman, R. A.: Temperature responses of the rat to action and interaction of chlorpromazine, reserpine and serotonin. Amer. J. Physiol. 195, 755–758 (1958).PubMedGoogle Scholar
  170. [166]
    Holgate, J. A., and B. T. Warner: Evaluation of antagonists of histamine, 5-hydroxytryptamine and acetylcholine in the guinea pig. Brit. J. Pharmacol. 15, 561–566 (1960).PubMedGoogle Scholar
  171. [167]
    Hollander, W., A. L. Michelson, and R. W. Wilkins: Serotonin and antiserotonines. I. Their circulatory, respiratory, and renal effects in man. Circulation 16, 246–262 (1957).PubMedGoogle Scholar
  172. [168]
    Hollister, L. E.: Clinical, biochemical and physiological effects of psilocybin. Arch. int. Pharmacodyn. 130, 42–52 (1961).PubMedGoogle Scholar
  173. [169]
    Hornykiewicz, O., H. Ehringer u. K. Lechner: Beeinflussung der Iproniazid-wirkung auf die Katecholamine und das 5-Hydroxytryptamin des Rattenhirnes durch Chlorpromazin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 241, 198 (1961).Google Scholar
  174. [170]
    Hukuhara, T., S. Nakayama, and R. Nauba: The effects of 5-hydroxytryptamine upon the intestinal motility, especially with respect to the intestinal mucosal intrinsic reflex. Jap. Physiol. 10, 420–426 (1960).Google Scholar
  175. [171]
    Innes, I. R.: Action of 5-hvdroxytryptamine on adrenaline receptors. Brit. J. Pharmacol. 19, 427–441 (1962).PubMedGoogle Scholar
  176. [172]
    Iversen, M., and B. Bull: The effect of 2,3-dimetlrvl-5-aminoidole on blood perssure. Acta pharmacol. (Kbh.) 9, 253–254 (1953).Google Scholar
  177. [173]
    Jacob, J.: Antagonists to the peripheral action of 5-hydroxytryptamine. Actualités Pharmacol. 13, 131–160 (1960).PubMedGoogle Scholar
  178. [174]
    Jacob, J., et F. Cugurra: Actions de la benzyl-l diméthyl-2,5 sérotonine (B.A.S.) sur les effets tensionnels de la sérotonine et sur l’activité cardiaque chez le chien et chez le lapin. Arch. int. Pharmacodyn. 123, 362–376 (1960).PubMedGoogle Scholar
  179. [175]
    Jacob, J., et G. Michaud: Effets de la 5-hydroxytryptamine et de la nicotine sur les hypertensions provoquées par la 5-hydroxytryptamine, la nicotine, la tryptamine et l’acétaldehyde. Arch. int. Pharmacodyn. 140, 92 (1962).PubMedGoogle Scholar
  180. [176]
    Jacob, J., et M. Poite-Bevierre: Actions de la serotonine et de la benzyl-1 dimethyl-2, 5 Serotonine sur le ceur isolé de lapin. Arch. int. Pharmacodyn. 127, 11–26 (1960).PubMedGoogle Scholar
  181. [177]
    Jaques, R., H. J. Bein, and R. Meier: 5-Hydroxytryptamine antagonists with special reference to the importance of sympathomimetic amines and isopropylnoradrenaline. Helv. physiol. pharmacol. Acta 14, 269–278 (1956).PubMedGoogle Scholar
  182. [178]
    Jaques, R., A. Rossi, E. Urech, H. J. Bein u. K. Hoffmann: Über Dibenzothiazepinderivate und ihre pharmakologische Wirkung. Helv. chim. Acta 42, 1265–1278 (1959).Google Scholar
  183. [179]
    Jensen, K.: The effect of antiserotonin (cyproheptadine) and antihistamine on cutaneous allergy. Acta allerg. (Kbh.) 15, 293–305 (1960).Google Scholar
  184. [180]
    Jensen, K.: Serotonin-producing tumors. A case treated with serotonin antagonists. Nord. Med. 69, 601–605 (1963).Google Scholar
  185. [181]
    Jordan, S. E., A. Lasslo, H. L. Livingston, H. Alperin, and A. Gersing: Comparative pharmacology of cocaine and the diethylamide derivative of cocaine. Arch. int. Pharmacodyn. 115, 452–473 (1958).PubMedGoogle Scholar
  186. [182]
    Julia, M., J. Igolen, M. Felix et J. Jacob: Sur quelques tryptamines substituées et leurs proprietés pharmacologiques. C. R. Acad. Sci. (Paris) 250, 1741–1743 (1960).Google Scholar
  187. [183]
    Katz, P., and Z. Fekete: Capillary permeability using coomassie blue as indicator. J. invest. Derm. 36, 37–46 (1961).Google Scholar
  188. [184]
    Kaminsky, A., and M. Asrilant: Therapeutic activity of a new antiserotonin preparation in dermatology. [Spanish.] Día méd. 32, 1970–1973 (1960).PubMedGoogle Scholar
  189. [185]
    Karja, J., N.T. Kärki, and E. Tala: Inhibition by methysergid of 5-hydroxytryptophan toxicity to mice. Acta pharmacol. (Kbh.) 18, 255–262 (1961).Google Scholar
  190. [186]
    Karlsberg, F., J. E. Adams, and H. W. Elliott: Inhibition and reversal of serotonin induced cerebral vasospasm. Surg. Forum 13, 425–427 (1962).Google Scholar
  191. [187]
    Kelemen, E.: The inhibition by sodium salicylate of oedema of the hind paw of the rat induced by 5-hydroxytryptamine. Brit. J. Pharmacol. 12, 28–29 (1957).PubMedGoogle Scholar
  192. [188]
    Kimura, E. T., P. R. Young, and R.K.Richards: Pharmacologic properties of N-p-chloro-benzhydryl-N’-methyl homopiperazine dihydrochloride (Homochlorcyclizine; SA-97), a serotonin antagonist. J. Allergy 31, 237–247 (1960).PubMedGoogle Scholar
  193. [189]
    King, T. O.: The antagonism of 5-hydroxytryptamine pneumoconstriction. Arch. int. Pharmacodyn. 110, 71–76 (1957).PubMedGoogle Scholar
  194. [190]
    Konzett, H.: The effects of 5-hydroxvtryptamine and its antagonists on tidal air. Brit. J. Pharmacol. 11, 289–294 (1956).PubMedGoogle Scholar
  195. [191]
    Kopf, R., u. I. Møeller Nielsen: Pharmakologische Eigenschaften einiger Phenylindolderivaten. Arch. int. Pharmacodyn. 119, 119–132 (1959).PubMedGoogle Scholar
  196. [192]
    Koshino, F.: Antagonistic action of γ-aminobutyric acid and its derivatives against acetylcholine, 5-hydroxytryptamine, nicotine, and histamine on guinea pig ileum. Nippon Seirigaku Zasshi 23, 161–169 (1961).PubMedGoogle Scholar
  197. [193]
    Krnjevic, K., and J. W. Phillis: Actions of certain amines on cerebral cortical neurones. Brit. J. Pharmacol. 20, 471–490 (1963).PubMedGoogle Scholar
  198. [194]
    Kroeger, D. C., and L. J. Lucco: Serotonin-induced apnea. J. Amer. pharm. Ass., sci. Ed. 49, 170–175 (1960).Google Scholar
  199. [195]
    Lanz, R.: Beobachtungen bei einem Karzinoidsyndrom. Schweiz. med. Wschr. 90, 1046–1048 (1960).PubMedGoogle Scholar
  200. [196]
    Lecomte, J.: 5-Hydroxytryptamine et membrane nictitante du chat. Arch. int. Pharmacodyn. 100, 457–465 (1955).PubMedGoogle Scholar
  201. [197]
    Lembeck, F.: Serotonin and the carcinoid syndrome. Gastroenterologia (Basel) 95, 189–208 (1961).Google Scholar
  202. [198]
    Lévy, J., et E. Michel-Ber: Contribution à l’action pharmacologique exercée par la sérotonine sur quelques organes isolés (intestin et oreillette). J. Physiol. (Paris) 48, 1051–1084 (1956).Google Scholar
  203. [199]
    Lewis, G. P.: The inhibition by morphine of the action of smooth muscle stimulants on the guinea pig ileum. Brit. J. Pharmacol. 15, 425–431 (1960).PubMedGoogle Scholar
  204. [200]
    Lewis, J. J., M. Martin-Smith, T. C. Muir, S. N. Nanjappa, and S. T. Reid: Benzo(b) thiophene derivatives. IV. The preparation and pharmacological activity of compounds related to serotonin and gramme. J. Med. Chem. 6, 711–716 (1963).PubMedGoogle Scholar
  205. [200a]
    Liacopoulos, P., B. N. Halpern et M. Liacopoulos-Briot: Modalités de l’inhibition des effects de l’histamine, des substances histamine-liberatrices et de la 5-hydroxytryptamine sur la permeabilité capillaire par leurs antagonistes. C. R. Acad. Sci. (Paris) 151, 1661–1666 (1957).Google Scholar
  206. [201]
    Linquette, M., P. Fossati, J. P. May, and H. Lebrun: Action of an antiserotonin substance on the ocular manifestations of BASEDOW’S diseases. Ann. Endocr. (Paris) 23, 457–464 (1962).Google Scholar
  207. [202]
    Long, R. F., and A. W. Lessin: Inhibition of 5-hydroxytryptamine uptake by platelet in vivo. Biochem. J. 82, 4P–5P (1962).Google Scholar
  208. [203]
    Ludány, G., T. Gáti, ST. Szabó u. J. Hideg: 5-Hydroxytryptamine (Enteramin, Serotonin), und die Darmzottbewegung. Arch. int. Pharmacodyn. 118, 62–69 (1959).PubMedGoogle Scholar
  209. [204]
    Magistretti, M., and L. Valzelli: Investigation of the inotropic action of serotonin on isolated hearts and auricles (Ital.). Boll. Soc. ital. Biol. sper. 31, 1035–1037 (1955).PubMedGoogle Scholar
  210. [205]
    Mallen, M. S., and J. Cueva: The rise of psychopharmacologic drugs in the treatment of allergic manifestations. [Spanish.] Alergia (Méx,) 8, 3–8 (1961).Google Scholar
  211. [206]
    Mansour, T. E.: The effect of lysergic acid diethylamide, 5-hydroxytryptamine and related compounds on the liver fluke, fasciola hepatica. Brit. J. Pharmacol. 12, 406 (1957).PubMedGoogle Scholar
  212. [207]
    Mansour, T. E., E. W. Sutherland, T. W. Rall, and E. Bueding: The effect of serotonin (5-hydroxytryptamine) on the formation of adenosine 3′, 5′-phosphate by tissue particles from the liver fluke, Fasciola hepatica. J. biol. Chem. 235, 466–470 (1960).PubMedGoogle Scholar
  213. [208]
    Marazzi, A. S., and E. R. Hart: Relationship of hallucinogens to adrenergic cerebral neurohumors. Science 121, 365–367 (1955).Google Scholar
  214. [209]
    Marazzi, A. S., Comparison of natural cerebral synaptic inhibitors. Inhibition of the nervous system and gamma-amino-butyric-acid. Proc. intern. Symp. Duarte, California, 1959, p. 531–539. Pergamon 1960.Google Scholar
  215. [210]
    Marczynski, T., and J. Vetulani: Further investigations on the pharmacological properties of 5-methoxy-N-methyltryptamine. Diss. pharm. (Krakow) 12, 67–84 (1960).Google Scholar
  216. [211]
    Marczynski, T., and J. Vetulani: The effect of bufotenin and serotonin on some autonomie reflexes of the circulatory system and peristaltic activity of the intestine. Diss. pharm. (Krakow) 13, 11–25 (1961).Google Scholar
  217. [212]
    Mariant, L., A. Mortari, and G. Sioli: Electrocardiographs modifications in anaphylactic shock in the guinea pig: intervention of serotonin and protective activity of chlorpromazine and ethylurethane. Mal. Cardiov. 2, 577–590 (1961).Google Scholar
  218. [213]
    Mariant, L., and R. Vertua: Electivity of the antagonism between chlorpromazine and serotonin in the lung. [Ital.] Ric. sci. 30, 1552–1555 (1960).Google Scholar
  219. [214]
    Mariant, L., and R. Vertua: Modification of the in vitro and in vivo binding of labeled serotonin in the presence of chlorpromazine. [Ital.] Minerva nucl. 5, 90–93 (1961).Google Scholar
  220. [215]
    Marley, E., and J. R. Vane: Tryptamine receptors in the central nervous system; effects of anesthetics. Nature (Lond.) 188, 441–444 (1963).Google Scholar
  221. [217]
    Marois, M.: Serotonine et accouchement. C. R. Acad. Sci. (Paris) 154, 1200–1203 (1960).Google Scholar
  222. [218]
    Martinez, A. M. V.: Antiserotoninas. [Spanish.] Medicina (Madr.) 30, 411–428 (1962).Google Scholar
  223. [219]
    Matthews, R. S.: The neuropharmacological effects of etryptamine (diethyltryptamine acetate). Arch. int. Pharmacodyn. 142, 90–110 (1963).PubMedGoogle Scholar
  224. [220]
    Mccawley, E. L., P. E. Leveque, and H. L. H. Dick: Certain actions of serotonin (5-hydroxytryptamine creatinine sulfate) on cardiac rhythm. J. Pharmacol. exp. Ther. 106, 406 (1961).Google Scholar
  225. [221]
    Mcisaac, W. M., P. A. Khairallah, and I. H. Page: 10-Methoxyharmalan, a potent serotonin antagonist which affects conditioned behavior. Science 134, 674–675 (1961).PubMedGoogle Scholar
  226. [222]
    Medaković, M.: Action of 5-hydroxytryptamine on the respiration of the dog and its interaction with morphine. Acta med. iugos. 12, 193–304 (1958).Google Scholar
  227. [223]
    Medaković, M.: Comparisons of antagonistic potencies of morphine-like analgesics towards 5-hydroxytryptamine on the guinea pig ileum, Arch. int. Pharmacodyn. 114, 201–209 (1958).Google Scholar
  228. [224]
    Meier, R., J. Tripod et E. Wirz: Classification d’une série d’antagonistes de la sérotonine et analyse de ses points d’attaque vasculaires périfériques. Arch. int. Pharmacodyn. 109, 55–77 (1957).PubMedGoogle Scholar
  229. [225]
    Mériel, P., R. Rufflé, A. Fournié, CH. Ayrolles et P. Cuq: Utilisation d’une antiserotonine (UML-491) en injections intra-articulaires. Rev. Rhum. 27, 149–155 (1960).Google Scholar
  230. [226]
    Michaux, R,: Catatonic action of 5-methoxytryptamine. Life Sci. 1, 617–619 (1962).PubMedGoogle Scholar
  231. [227]
    Moore, K. E., A. S. Milton, and R. E. Gosselin: Effect of 5-hydroxytryptamine on the respiration of excised lamellibranch gill. Brit. J. Pharmacol. 17, 278–285 (1961).PubMedGoogle Scholar
  232. [228]
    Mörsdorf, K., u. H.H. Bode: Zur Beeinflussung der permeabilitätssteigernden Wirkung des Serotonins durch verschiedenartige Pharmaka. Arch. int. Pharmacodyn. 118, 292–297 (1959).PubMedGoogle Scholar
  233. [229]
    Moussatche, H., and N. Alvares Pereira: Release of ACTH by 5-hydroxytryptamine. Acta physiol. lat.-amer. 7, 71–75 (1957).PubMedGoogle Scholar
  234. [230]
    Murelli, B., A. Valsecchi, and L. Valzelli: On the activity of the antiserotonin molecule: the 1,1 benzyl-2-methyl-5-methoxytryptamine (BAS) on some isolated organs and on the diuresis. [Ital.] Boll. Soc. ital. Biol. sper. 33, 859–863 (1957).Google Scholar
  235. [231]
    Naers, K., and S. Schanche: Effect of regitine on 5-hydroxytryptamine in rabbit serum. Acta pharmacol. (Kbh.) 12, 406–410 (1956).Google Scholar
  236. [232]
    Naers, K., and K. H. Skramstad: The action of 1-hydrazinophthalazine (hydralazine, apresoline) and the relationship between hydralazine and 5-hydroxytryptamine (enteramine, serotonin). Acta pharmacol. (Kbh.) 10, 178–198 (1954).Google Scholar
  237. [233]
    Neuman, M.: Serotonin and anti-serotonins. Concours. méd. 85, 2187–2196 (1963).Google Scholar
  238. [234]
    Niaussat, P., J. Drouet, and J. Berthou: Influence of 5-hydroxytryptamine used at pharmacologic doses in the normal or experimentally diabetic rabbit. Med. exp. (Basel) 4, 197–206 (1961).Google Scholar
  239. [235]
    Nielsen, I. M., and K. Neuhold: The comparative pharmacology and toxicology of the trans isomer of 2-chloro-9-(3′-dimethylaminopropylidene) thiaxanthen. Acta pharmacol. (Kbh.) 15, 335–355 (1959).Google Scholar
  240. [235a]
    Nieschulz, O., J. Hoffmann u. K. Popendiker: Pharmacologische Untersuchungen über N-Methylpiperazinyl-N’-propyl-phenothiazin. Arzneimittel-Forsch. 8, 199–210 (1958).Google Scholar
  241. [236]
    Nikodijevic, B., and S. Vanov: The influence of thenalidine on reserpine-and serotonin-induced gastric ulcers in rats. Experientia (Basel) 16, 464 (1960).Google Scholar
  242. [237]
    Nir, I., O. Peczenik, and E. Weissenberg: Influence of anticholinergic drugs on actions of cholinesters, histamine and serotonin. Abstr. XXth Int. Physiol. Congr., p. 680–681, Brussels 1956.Google Scholar
  243. [238]
    Northover, B. J., and G. Subramanian: A study of possible mediators of inflammatory reactions in the mouse foot. Brit. J. Pharmacol. 18, 346–355 (1962).PubMedGoogle Scholar
  244. [239]
    O’brien, D. J., W. F. Hughes, and J. Newberne: Influence of lysergic acid diethylamide on experimental allergic encephalomyelitis. Proc. Soc. exp. Biol. (N.Y.) 111, 490–493 (1962).Google Scholar
  245. [240]
    Ostfield, A. M.: Migraine headache, its physiology and biochemistry. J. Amer. med. Ass. 174, 1188–1190 (1960).Google Scholar
  246. [241]
    Outschoorn, A. S., and J. Jacob: A study of antagonists of 5-hydroxytryptamine and catechol amines on the rat’s blood pressure. Brit. J. Pharmacol. 15, 131–139 (1960).PubMedGoogle Scholar
  247. [242]
    Page, I. H.: Serotonin (5-hydroxytryptamine); the last four years. Physiol. Rev. 38, 277–335 (1958).PubMedGoogle Scholar
  248. [242a]
    Page, I. H., and J. W. Mccubbin: Modification of vascular response to serotonin by drugs. Amer. J. Physiol. 174, 436–444 (1953).PubMedGoogle Scholar
  249. [243]
    Parratt, J. R., and G.B. West: Inhibition of oedema production in the rat. J. Physiol. (Lond.) 135, 24–25 (1956).Google Scholar
  250. [243a]
    Parratt, J. R., and G.B. West: Inhibition by various substances of oedema formation in the hind paw of the rat induced by 5-hydroxytryptamine, histamine, dextran, eggwhite and compound 48/80. Brit, J. Pharmacol. 13, 65–70 (1958).Google Scholar
  251. [244]
    Passow, H., H. Schniewind, and C. Weiss: The action of 5-hydroxytryptamine on the vascular system of isolated rat kidneys. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 240, 179–286 (1960).Google Scholar
  252. [245]
    Pennefeather, I. N., and R. H. Thorp: The influence of beta-tetrahydronaphthylamine and a derivative on the central effects of 5-hydroxytryptamine, reserpine, and iproniazid. J. Pharm. Pharmacol. 10, 249–252 (1958).Google Scholar
  253. [246]
    Pfeifer, A. K., E. Satory, and I. Pataky: Effect of tranquilizing drugs on the pharmacological actions of diethyltryptamine. Acta physiol. Acad. Sci. hung. 19, 225–233 (1961).PubMedGoogle Scholar
  254. [247]
    Pinsker, W., and K. H. Thayer: Treatment of allergic conditions with methysergide (1-methyl-D-lysergic acid butanolamide bimaleate), a new antiserotonin drug. A pilot study. Ann. Allergy 21, 200–205 (1963).Google Scholar
  255. [248]
    Poulson, E., and J. M. Robson: Prevention by antagonists of the toxic action of 5-hydroxytryptamine on pregnancy. Brit. J. Pharmacol. 21, 150–154 (1963).PubMedGoogle Scholar
  256. [249]
    Quadbeck, G., u. E. Röhm: Über substituierte Gramine als wirksame Serotonin-Antagonisten. Hoppe-Seylers Z. physiol. Chem. 297, 229–237 (1954).PubMedGoogle Scholar
  257. [250]
    Rapport, M. M., and G. B. Koelle: The action of antihistaminics and atropine in blocking the spasmogenic activity of serotonin on the guinea pig ileum. Arch. int. Pharmacodyn. 92, 464–470 (1952).Google Scholar
  258. [251]
    Reid, G., and M. Rand: Physiological actions of the partially purified serum vasoconstrictor (serotonin). Aust. J. exp. Biol. med. Sci. 29, 401–415 (1951).PubMedGoogle Scholar
  259. [252]
    Reid, G., and M. Rand: Pharmacological actions of synthetic 5-hydroxytryptamine (serotonin, thrombocytin). Nature (Lond.) 169, 801–802 (1952).Google Scholar
  260. [253]
    Reuse, J. J.: Pharmacological properties of hydroxyzine. Arch. int. Pharmacodyn. 114, 471–474 (1958).PubMedGoogle Scholar
  261. [254]
    Rinaldi, F.: The effects of two antiserotonin substances BAS and BAB and of bufotenin on the spontaneous electrical activity of the brain. J. nerv. ment. Dis. 126, 272–283 (1958).PubMedGoogle Scholar
  262. [255]
    Robertson, P. A.: An antagonism of 5-hvdroxytryptamine by atropine. J. Physiol. (Lond.) 121, 54 (1953).Google Scholar
  263. [256]
    Rocha E. Silva, M., J. R. Valle, and Z. P. Picarelli: A pharmacological analysis of the mode of action of serotonin upon the guinea pig ileum. Brit. J. Pharmacol. 8, 378–388 (1953).Google Scholar
  264. [257]
    Rodnight, R., and H. Mcilwain: Serotonin, LSD and mental status. Brit. med. J. 1956 I, 108.Google Scholar
  265. [258]
    Rose, J. C., and E. J. Lazaro: Pulmonary vascular responses to serotonin and effects of certain serotonin antagonists. Circulat. Res. 6, 283–288 (1958).PubMedGoogle Scholar
  266. [259]
    Rothlin, E.: Pharmacology of lysergic acid diethylamide (LSD) and some of its related compounds. In: Psychotropic drugs, ed. by S. Garattini and V. Ghetti, p. 36–47. Amsterdam: Elsevier Press 1957a.Google Scholar
  267. [260]
    Rothlin, E.: Lysergic acid diethylamide and related substances. Ann. N.Y. Acad. Sci. 66, 668–676 (1957b).PubMedGoogle Scholar
  268. [261]
    Rothlin, E.: Pharmacology of lysergic acid diethylamide and some of its related compounds. J. Pharm. Pharmacol. 9, 569–587 (1957c).PubMedGoogle Scholar
  269. [262]
    Rudy, L. H., E. Costa, F. Rinaldi, and H. E Himwich: Clinical evaluation of BAS (benzyl analogue of serotonin) a tranquilizing drug. J. nerv. ment. Dis. 126, 284–293 (1958).PubMedGoogle Scholar
  270. [263]
    Rummel, W.: Comparative study of the antagonistic properties of phenothiazine derivatives against serotonin, adrenaline, and histamine in the terminal ileum of the guinea pig. Med. exp. (Basel) 4, 126–134 (1961).Google Scholar
  271. [264]
    Sabelli, H. C., and I. Sinay: Pressor effects of adrenergic agents and serotonin after administration of imipramine. Arzneimittel-Forsch. 10, 935–936 (1960).Google Scholar
  272. [265]
    Sacchi, U., F. Bonamini, G. Dolce, and L. Garello: Lysergic acid diethylamide and 5-hydroxytryptamine induced catalepsy in the dog. [Ital.] Boll. Soc. ital. Biol. sper. 31, 665–667 (1955).Google Scholar
  273. [266]
    Sai-Halâsz, A.: Effect of antiserotonin on the experimental psychosis induced by dimethyltryptamine. Experientia (Basel) 18, 137–138 (1962).Google Scholar
  274. [267]
    Salmoiraghi, G. C., J. W. Mccubbin, and I. H. Page: Effects of d-lysergic acid diethylamide and its bromo derivative on cardiovascular responses to serotonin and on arterial pressure. J. Pharmacol. exp. Ther. 119, 240–247 (1957).PubMedGoogle Scholar
  275. [268]
    Salmoiraghi, G. C., and I. H. Page: Effects of LSD-25, BOL-148, bufotenine, mescaline and ibogaine on the potentiation of hexobarbital hypnosis produced by serotonine and reserpine. J. Pharmacol. exp. Ther. 120, 20–25 (1957).PubMedGoogle Scholar
  276. [269]
    Sano, L, Y. Kakimoto u. T. Okamoto: Der Einfluß von Phenothiazinderivaten auf den Serotoninabbau. Nervenarzt 28, 363–364 (1957).PubMedGoogle Scholar
  277. [270]
    Savini, E. C.: The antagonism between 5-hydroxytryptamine and certain derivatives of lysergic acid. Brit. J. Pharmacol. 11, 313–317 (1956).PubMedGoogle Scholar
  278. [271]
    Saxena, A., B. K. Bhattacharya, and B. Mukerji: Behavioural studies in fish with mescaline, LSD, and thiopropazate and their interactions with serotonin and dopa. Arch. int. Pharmacodyn. 140, 327–335 (1962).PubMedGoogle Scholar
  279. [272]
    Schaeppi, U.: Comparison of serotonin with directly or indirectly acting compounds in their effect on the nictitating membrane of spinal cats. J. Pharmacol. exp. Ther. 139, 330–336 (1963).PubMedGoogle Scholar
  280. [273]
    Scherbel, A. L., and J.W. Harrison: Response to serotonin and its antagonists with rheumatoid arthritis and related diseases. Angiology 10, 29–33 (1959).PubMedGoogle Scholar
  281. [274]
    Schlichtegroll, A. v.: Zur Pharmakologie verschiedener Thiophenylpyridylamin-derivate. Arzneimittel-Forsch. 7, 237–252 (1957).Google Scholar
  282. [275]
    Schmid, E., L. Zicha, F. Scheiffarth u. O. Buttner: Untersuchungen über den Antagonismus von antihistaminen gegen Serotonin. Arzneimittel-Forsch. 9, 474–476 (1959).Google Scholar
  283. [276]
    Schmidt, J.: Die Beeinflussung des Serotonin-Ödems der Rattenpfote durch Noradrenalin und Adrenalin. Acta biol. med. germ. 10, 194–196 (1963).PubMedGoogle Scholar
  284. [277]
    Schmidt, J., u. H. Matthies: Über einen zentralen Serotonin-Noradrenalin-Antagonismus. Acta biol. Med. germ. 7, 107–109 (1961).Google Scholar
  285. [278]
    Schmitt, H., et H. Schmitt: Sur les effects hypertenseurs de la reserpine après certains sympathicomimetiques. Arch. int. Pharmacodyn. 120, 251–262 (1959).PubMedGoogle Scholar
  286. [279]
    Schneckloth, R. E., I. H. Page, F. Delgreco, and A. C. Corcoran: Effects of serotonin antagonists in normal subjects and patients with carcinoid tumours. Circulation 16, 523–532 (1957).PubMedGoogle Scholar
  287. [280]
    Schneider, J. A., and R. K. Rinehart: Circulatory interactions of serotonin and reserpine in dogs. Arch. int. Pharmacodyn. 105, 253–268 (1956).PubMedGoogle Scholar
  288. [281]
    Schneider, J. A., and F. F. Yonkman: Species differences in the respiratory and cardiovascular response to serotonin (5-hydroxytryptamine). J. Pharmacol. exp. Ther. 111, 84–98 (1954).PubMedGoogle Scholar
  289. [282]
    Schwarz, B. E., K. G. Wakim, R. G. Blickford, and F. R. Lichtenfeld: Behavioral and electroencephalographic effects of hallucinogenic drugs. Arch. Neurol. Psvchiat. (Chic.) 75, 83–90 (1956).Google Scholar
  290. [283]
    Scott, K. G., and R. S. Stone: The anti-tumor action of lysergic acid derivatives and their serotonin-blocking effect as reflected by the I131 distribution in rats. Cancer Res. 19, 783–787 (1959).PubMedGoogle Scholar
  291. [284]
    Shaw, E., and D. W. Woolley: Yohimbine and ergot alkaloids as naturally occurring antimetabolites of serotonin. J. biol. Chem. 203, 979–989 (1953).PubMedGoogle Scholar
  292. [285]
    Shaw, E., and D. W. Woolley: Pharmacological properties of some antimetabolites of serotonin having unusually high activity on isolated tissues. J. Pharmacol. exp. Ther. 111, 43–53 (1954).PubMedGoogle Scholar
  293. [286]
    Shaw, E., and D. W. Woolley: Benzyldimethylbufotenin, a powerful antimetabolite of serotonin. Proc. Soc. exp. Biol. (N.Y.) 93, 217–220 (1956).Google Scholar
  294. [287]
    Shaw, E., and D. W. Woolley: Methylserotonines as potent metabolites of serotonin active both in vitro and in vivo. J. Pharmacol. exp. Ther. 116, 164–176 (1956).PubMedGoogle Scholar
  295. [288]
    Shaw, E., and D. W. Woolley: Indole carboxamidines and aminomethylindoles as metabolites of serotonin. J. Amer. chem. Soc. 79, 3561–3564 (1957a).Google Scholar
  296. [289]
    Shaw, E., and D. W. Woolley: Synthesis and demonstration of antiserotonin activity of l-benzyl-2-methyl-5-hydroxytryptamine (BAS-phenol). Proc. Soc. exp. Biol. (N.Y.) 96, 439–442 (1957b).Google Scholar
  297. [290]
    Shore, P. A., and B. B. Brodie: LSD-like effects elicited by reserpine in rabbits pretreated with iproniazid. Proc. Soc. exp. Biol. (N.Y.) 94, 433–354 (1957).Google Scholar
  298. [291]
    Shore, P. A., S. L. Silver, and B. B. Brodie: Interaction of serotonin and LSD in the CNS. Experientia (Basel) 11, 272–273 (1955).Google Scholar
  299. [292]
    Sicuteri, F.: Premier essai therapeutique de la migraine par une substance antiserotoninique. Acta allerg. (Kbh.), Suppl. 7, 128–135 (1960).Google Scholar
  300. [293]
    Sicuteri, F. G. Franchi, and S. Michelacci: Inhibition by lysergic acid derivatives of bronchospasm induced in guinea pigs by serotonin aerosol. Med. exp. (Basel) 3, 89–94 (1960).Google Scholar
  301. [294a]
    Sigg, E. B., L. Gyermek, R.T. Hill and H. C.Y. Yen: Neuropharmacology of some harmane derivatives. Arch. int. Pharmacodyn. 149, 164–176 (1964).PubMedGoogle Scholar
  302. [294]
    Sigg, E. B., L. Soffer, and L. Gyermek: Influence of imipramine and related psychoactive agents on the effect of 5-hydroxytryptamine and catecholamines on the cat nictitating membrane. J. Pharmacol. exp. Ther. 142, 13–20 (1963).PubMedGoogle Scholar
  303. [295]
    Sinha, Y. K., and G. B. West: The antagonism between local anesthetic drugs and 5-hydroxytryptamine. J. Pharm. Pharmacol. 5, 370–374 (1953).PubMedGoogle Scholar
  304. [296]
    Sankar, D. V. S., D. Sankar, E. Phipps, and E. Gold: Effect of administration of lysergic acid diethylamide on serotonin levels in the body. Nature (Lond.) 191, 499–500 (1961).Google Scholar
  305. [297]
    Sjoerdsma, A., H. Weissbach, L. L. Terry, and S. Udenfriend: Further observations on patients with malignant carcinoid. Amer. J. Med. 23, 5–15 (1957).PubMedGoogle Scholar
  306. [298]
    Slater, I. H., K. H. Davis, D. E. Leary, and E. Boyd: The action of serotonin and LSD on spinal reflexes. J. Pharmacol. exp. Ther. 113, 48 (1955).Google Scholar
  307. [299]
    Sletzinger, M., W. V. Ruyle, and W. A. Gaines: Tryptamine derivatives. Appl. Feb. 8, 1957. U.S. Patent 2,995,566.Google Scholar
  308. [300]
    Smith, G., and A. N. Smith: The role of serotonin in experimental pulmonary embolism. Surg. Gynec. Obstet. 101, 691–700 (1955).PubMedGoogle Scholar
  309. [301]
    Snow, P. J. D., J. E. Lennard-Jones, G. Curzon, and R. S. Stacey: Humoral effects of metastasing carcinoid tumors. Lancet 1965 II, 1004–1009.Google Scholar
  310. [302]
    Soffer, L., and L. Gyermek: The interaction of imipramine, its derivatives and phenothiazines with 5-HT, epinephrine and norepinephrine. Fed. Proc. 20, 396 (1961).Google Scholar
  311. [303]
    Sollero, L., and G. S. Kurtz: Blocking of the action of substances related to tryptamine on smooth muscle by 1-methyllysergic acid butanolamide (UML-491), Hospital (Rio de J.) 62, 9–11 (1962).Google Scholar
  312. [304]
    Sollero, L., I. H. Page, and G. C. Salmoiraghe: Bromo LSD: a highly potent serotonin antagonist. J. Pharmacol. exp. Ther. 117, 10–15 (1956).PubMedGoogle Scholar
  313. [305]
    Spies, T. D., and R. E. Stone: Effect of serotonin on blood pressure and lack of effect of antimetabolite. J. Amer. med. Ass. 150, 1599–1600 (1952).Google Scholar
  314. [306]
    Sprince, H.: Indole metabolism in mental illness. Clin. Chem. 7, 203–230 (1961).Google Scholar
  315. [307]
    Stacey, R. S.: Uptake of 5-hydroxytryptamine by platelets. Brit. J. Pharmacol. 16, 284–295 (1961).PubMedGoogle Scholar
  316. [308]
    Starbuck, C., and H. C. Heim: Some in vitro effects of chlorpromazine, LSD and 5-hydroxytryptamine of rat brain. J. Amer. pharm. Ass., sci. Ed. 48, 251–254 (1959).Google Scholar
  317. [309]
    Stone, C. A., H. C. Wenger, C. T. Ludden, J. M. Stavorski, and A. C. Ross: Antiserotonin-antihistaminic properties of cyproheptadine. J. Pharmacol. exp. Ther. 131, 73–84 (1961).Google Scholar
  318. [310]
    Stormorken, H.: The antiserotonin effect of the benzyl analog of bufotenin (BAB) and the benzyl analog of serotonin (BAS) in the isolated guinea pig lung. Arch. int. Pharmacodyn. 119, 232–237 (1959).PubMedGoogle Scholar
  319. [311]
    Strandtmann, M. V., M. P. Cohen, and J. Shavel jr.: Acyltryptamines. II. Synthesis of acyltryptamines, indazoles and azepinoindoles from the acylpenylhydrazones of 2,3-piperidinedione. J. Med. Chem. 6, 719–725 (1963).Google Scholar
  320. [312]
    Supniewski, J. V., T. Marczynski, and S. Misztal: Biological properties of melatonin (5-methoxy-N-acetyltryptamine). Bull. Acad. pol. Sci., Ser. Sci. Biol. 8, 483–487 (1960).Google Scholar
  321. [313]
    Szara, S.: Behavioral correlates of 6-hydroxylation and the effect of psychotropic tryptamine derivatives on brain serotonin levels. Proc. Vth Internat. Neurochem. Symp. 1962, p. 425–432.Google Scholar
  322. [314]
    Szara, S., and J. Axelrod: Hydroxylation and N-demethylation of N.N-dimethyltryptamine. Experientia (Basel) 15, 216–217 (1959).Google Scholar
  323. [315]
    Szara, S., E. Hearst, and F. Putney: Metabolism and behavioral action of psychotropic tryptamine homologues. Int. J. Neuropharm. 1, 111–117 (1962).Google Scholar
  324. [316]
    Taeschler, M.: Serotonin blocking effect and some central actions of lysergic acid derivatives. Abstr. XXth Int. Congr. Physiol., p. 873–874, Brussels 1956.Google Scholar
  325. [317]
    Takeo, Y.: Pharmacological studies on clavine-type alkaloids. II. The effect of clavinetype alkaloids on the cardiovascular system and several organs and the interaction between them and 5-HT action. Folia pharmacol. jap. 58, 417–425 (1962).PubMedGoogle Scholar
  326. [318]
    Tedeschi, D. H., R. E. Tedeschi, L. Cook, P. A. Mattis, and E. J. Fellows: The neuropharmacology of trifluoperazine: a potent psychotherapeutic agent. Arch. int. Pharmacodyn. 122, 129–143 (1959).PubMedGoogle Scholar
  327. [319]
    Tedeschi, D. H., R. E. Tedeschi, and E. J. Fellows: Central (nervous system) serotonin antagonist activity of a number of phenothiazines. Arch. int. Pharmacodyn. 132, 172–179 (1961a).PubMedGoogle Scholar
  328. [320]
    Tedeschi, D. H., R. E. Tedeschi, and E. J. Fellows: Interaction of neuroleptics with serotonin in the central nervous system. Rev. canad. Biol. 20, 209–214 (1961b).PubMedGoogle Scholar
  329. [321]
    Tedeschi, D. H., P. J. Fowler, H. Green, and E. J. Fellows: N-methyl-alpha-methyltryptamine a potent monoamine oxidase inhibitor and tryptamine antagonist. Biochem. Pharmacol. 11, 481–485 (1962).PubMedGoogle Scholar
  330. [322]
    Theobald, W., u. R. Domenjoz: Das Serotonin-Ödem der Ratte und seine Beeinflussung durch Antiphlogistica. Arzneimittel-Forsch. 8, 18–19 (1958).Google Scholar
  331. [323]
    Thompson, J. W.: Studies on the responses of the isolated nictitating membrane of the cat. J. Physiol. (Lond.) 141, 46–72 (1958).Google Scholar
  332. [324]
    Trapold, J. H., R. Mulford, and D. Grohman: Pharmacological and cardiovascular effects of 1-methyl lysergic acid butanolamide bimaleinate; a potent antiserotonin compound. Fed. Proc. 19, 87 (1960).Google Scholar
  333. [325]
    Trendelenburg, U.: The action of 5-hydroxytryptamine on the nictitating membrane and on the superior cervical ganglion of the cat. Brit. J. Pharmacol. 11, 74–80 (1956).PubMedGoogle Scholar
  334. [326]
    Trendelenburg, U.: The action of morphine on the superior cervical ganglion and on the nictitating membrane of the cat. Brit. J. Pharmacol. 12, 79–85 (1957).PubMedGoogle Scholar
  335. [327]
    Trendelenburg, U.: The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. J. Pharmacol. exp. Ther. 130, 450–460 (1960).PubMedGoogle Scholar
  336. [328]
    Tripod, J.: Charactérisation générale des effets pharmacodynamiques de substances psychotropiques. In: Psychotropic drugs, ed. by S. Garattini and V. Ghetti, p. 437. Amsterdam: Elsevier Publ. Co. 1957.Google Scholar
  337. [329]
    Trout, D. L.: Interaction of serotonin and LSD in the Siamese fighting fish. J. Pharmacol. exp. Ther. 121, 130–135 (1957).PubMedGoogle Scholar
  338. [330]
    Uda, T.: The mode of inhibiting action of guaiazulene and some other antiinflammatory agents on anaphylactoid edemas. Nippon Yakurigaku Zasshi 56, 1151–1163 (1960).Google Scholar
  339. [331]
    Vaccarezza, J. R., and A. Bochi: Effect of corticotropin and cortisol on urinary excretion of metabolites of serotonin (5-HIAA) in normal subjects and respiratory allergic patients. Ann. Allergy 22, 12–19 (1964).PubMedGoogle Scholar
  340. [332]
    Valdecasas, F. G., F. Calvet, E. Cuenca u. J. A. Salva: Die potenzierende Wirkung verschiedener psvchoaktiver Substanzen auf Adrenalin und Serotonin. Arzneimittel-Forsch. 6, 594–596 (1956).Google Scholar
  341. [333]
    Van Arman, C. G.: The antidiuretic effect of 5-hydroxytryptamine in the rat as influenced by dibenamine. Arch. int. Pharmacodyn. 108, 356–365 (1956).Google Scholar
  342. [334]
    Vane, J. R.: A sensitive method for the assay of 5-hydroxytryptamine. Brit. J. Pharmacol. 12, 344–349 (1957).PubMedGoogle Scholar
  343. [335]
    Vane, J. R.: The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. Brit. J. Pharmacol. 14, 87–98 (1959).PubMedGoogle Scholar
  344. [336]
    Vane, J. R., H. O. J. Collier, S. J. Corne, E. Marley, and P. B. Bradley: Tryptamine receptors in the central nervous system. Nature (Lond.) 191, 1068–1069 (1961).Google Scholar
  345. [337]
    Venulet, J.: Correlation of the antiserotonin and depressor activities of some phenothiazine derivatives. Acta physiol. pol. 12, 281–290 (1961).PubMedGoogle Scholar
  346. [338]
    Vercellone, A., and B. Asero: 5-hydroxytryptamine (enteramine, serotonin) a possibly new hormone. II. Farmaco, Ed. sci. 9, 629–641 (1954).Google Scholar
  347. [339]
    Vogel, G., and M. L. Marek: Inhibition of rat-paw edema of various origins by serotonin antagonists. Arzneimittel-Forsch. 11, 1051–1054 (1961).Google Scholar
  348. [340]
    Vogel, G., u. M. L. Marek: Zur Pharmakologie einiger Saponine. Arzneimittel-Forsch. 12, 815–825 (1962).Google Scholar
  349. [341]
    Votava, Z., and J. Lamplová: Antiserotonin effect of derivatives of d-lysergic acid (cycloalkylamides, LSD, ergometrine) and chlorpromazine in rats. [Czech.] Activ. nerv. sup. (Praha) 1, 269–275 (1959).Google Scholar
  350. [342]
    Votava, Z., I. Podvalova, and M. Semonský: Studies on the pharmacology of d-lysergic acid cycloalkylamides. Arch. int. Pharmacodyn. 115, 114–130 (1958).PubMedGoogle Scholar
  351. [343]
    Walaszek, E. J., and L. G. Abood: Fixation of 5-hydroxytryptamine by brain mitochondria. Fed. Proc. 16, 133 (1957).Google Scholar
  352. [344]
    Walaszek, E. J., and J. E. Chapman: Bulbocapnine: an adrenergic and serotonin blocking agent. J. Pharmacol. exp. Ther. 138, 285–290 (1962).Google Scholar
  353. [345]
    Weidmann, H., u. A. Cerletti: Untersuchungen über die pressorische Wirkung des 5-Hydroxytryptamin (Serotonin). Arch. int. Pharmacodyn. 111, 98–107 (1957).PubMedGoogle Scholar
  354. [346]
    Weis, J.: Investigations on some experimental inflammations in mouse paws. Med. exp. (Basel) 8, 1–11 (1963).Google Scholar
  355. [347]
    Welsh, J. H.: Excitation of the heart of Venus mercenaria. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 219, 23–29 (1953).Google Scholar
  356. [348]
    Welsh, J. H.: Marine invertebrate preparations useful in the bioassay of acetylcholine and 5-hydroxytryptamine. Nature (Lond.) 173, 955–956 (1954).Google Scholar
  357. [349]
    Westermann, E.: Über die Wirkung von 5-hydroxytryptamine (Serotonin) auf die Atmung. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 233, 518–530 (1958).Google Scholar
  358. [349a]
    Wielding, S.: Pharmacological and toxicological studies on beta-diethylaminoethyl phenothiazine-10-carboxylate hydrochloride (Transergan), a new spasmolytic and anti-Parkinsonism agent. Acta pharmacol. (Kbh.) 13, 59–79 (1957).Google Scholar
  359. [350]
    Wielding, S.: Secergan, a quaternary phenothiazine compound having anticholinergic and ganglion-blocking actions. Acta pharmacol. (Kbh.) 14, 112–129 (1958).Google Scholar
  360. [351]
    Wilhelmi, G.: Ulcerogenic effect of 5-hydroxytryptamine on rat stomach and influence of various drugs. Helv. physiol. pharmacol. Acta 15, 83 (1957).Google Scholar
  361. [352]
    Wilhelmi, G., u. W. Schindler: Über die gastrotrope Wirkung von 5-Hydroxytryptamin, seiner Vorstufen und der entsprechenden Isomeren bei der Ratte. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 236, 49–51 (1959).Google Scholar
  362. [353]
    Wilkins, R. W.: Serotonin, antiserotonins and hypertension. New Engl. J. Med. 255, 115–118 (1956).PubMedGoogle Scholar
  363. [354]
    Wilkins, R. W., and W. Hollander: Serotonin and antiserotonines. II. Clinical studies especially in essential hypertension with the benzyl analogue of serotonin (BAS) Circulation 16, 256–262 (1957).PubMedGoogle Scholar
  364. [355]
    Wirth, W., R. Gosswald, u. W. Vater: Zur Pharmakologie acylierter Phenothiazin-Derivate. Arch. int. Pharmacodyn. 123, 78–114 (1959).PubMedGoogle Scholar
  365. [356]
    Woolley, D. W.: Probable evolutionary relationship of serotonin and indoleacetic acid, and some practical consequences therefrom. Nature (Lond.) 180, 630–633 (1957).Google Scholar
  366. [357]
    Woolley, D. W.: Convenient method for assay in vivo of antimetabolites of serotonin. Proc. Soc. exp. Biol. (N.Y.) 98, 367–370 (1958).Google Scholar
  367. [358]
    Woolley, D. W.: Highly potent antimetabolites of serotonin with little serotonin-like action. Biochem. Pharmacol. 3, 51–59 (1959).PubMedGoogle Scholar
  368. [359]
    Woolley, D. W., and N. K. Campbell: Serotonin-like and antiserotonin properties of psilocybin and psilocin. Science 136, 777–778 (1962).PubMedGoogle Scholar
  369. [360]
    Woolley, D. W., and P. M. Edelman: Displacement of serotonin from tissue by a specific antimetabolite. Science 127, 281–282 (1958).PubMedGoogle Scholar
  370. [361]
    Woolley, D. W., and E. Shaw: Yohimbine and ergotoxin as naturally occurring antimetabolities of serotonin. Fed. Proc. 12, 292 (1953).Google Scholar
  371. [362]
    Woolley, D. W., and E. Shaw: Differentiation between receptors for serotonin and tryptamine by means of the exquisite specificity of antimetabolites. J. Pharmacol. exp. Ther. 121, 13–17 (1957a).PubMedGoogle Scholar
  372. [363]
    Woolley, D. W., and E. Shaw: Evidence for the participation of serotonin in mental processes. Ann. N.Y. Acad. Sci. 66, 649–667 (1957b).PubMedGoogle Scholar
  373. [364]
    Wright, A. M., M. Moorhead, and J. H. Welsh: Actions of derivatives of lysergic acid on the heart of venus mercenaris. Brit. J. Pharmacol. 18, 440–450 (1962).PubMedGoogle Scholar
  374. [365]
    Wurtman, R. J., J. Axelrod, and L. S. Phillips: Melatonin synthesis in the pineal gland: Control. by light. Science 142, 1071–1073 (1963).Google Scholar
  375. [366]
    Wylie, D. W.: Pharmacology of some stereoisomers of hydroxytropane derivatives of phenothiazine. J. Pharmacol. exp. Ther. 127, 276–280 (1959).PubMedGoogle Scholar
  376. [367]
    Yoon, S. R.: Phenoxybenzamine as an antagonist of 5-hydroxytryptamine. Kor. med. J. 12, 67–72 (1960).Google Scholar
  377. [368]
    Yu, R., I. Yuchenok, and L. A. Nazarov: Relation of serotonin to central adrenoreceptive and cholinoreceptive systems in the mechanism of electroencephalogram activation. Dokl. Akad. Nauk SSSR 146, 1237–1240 (1962).Google Scholar
  378. [369]
    Yui, T., and Y. Takeo: Neuropharmacological studies on a new series of ergot alkaloids. Jap. J. Pharmacol. 7, 157–161 (1958).PubMedGoogle Scholar
  379. [370]
    Zakusov, V. V.: Principles of pharmacological influences on coronary chemoreflexes. Arch. int. Pharmacodyn. 140, 646–655 (1962).PubMedGoogle Scholar
  380. [371]
    Zakusov, V. V.: Some serotonin antagonists. Farmakol. i Toksikol. 26, 131–138 (1963).Google Scholar
  381. [372]
    Zanowiak, P., and M. J. Rodman: A study of LSD-serotonin central interaction. J. Amer. Pharm. Ass., sci. Ed. 48, 165–168 (1959).Google Scholar
  382. [373]
    Zicha, L., F. Scheiffarth, H. Koschera, E. Schmid u. N. Graf: Vergleichende Untersuchungen mit neueren Corticoid-Derivaten am Histamin-und Serotonin-Asthma des Meerschweinchens. Arzneimittel-Forsch. 10, 728–731 (1960).Google Scholar
  383. [374]
    Zicha, L., and B. Bregulla: Comparative studies on the antagonistic effects of phenylbutazone and hydroxyphenylbutazone toward histamine, serotonin, and acetylcholine. Arzneimittel-Forsch. 12, 474–477 (1962).Google Scholar
  384. [375]
    Zileli, T., L. F. Chapman, and H. G. Wolff: Anti-inflammatory action of UML-491 (1-methyl-D-lysergic acid butanolamide dimaleate) demonstrated by the granuloma pouch technique in rats. Arch. int. Pharmacodyn. 136, 463–464 (1962).Google Scholar
  385. [376]
    Geigy, J. R., A-G.: Amines derived from dibenzocycloheptane. Belg. pat. 615, 025, September 13, 1962.Google Scholar
  386. [377]
    Merck & Co., Inc.: Tryptamine Compounds. British pat. 859, 223, January 18, 1961.Google Scholar

Copyright information

© Springer-Verlag, Berlin · Heidelberg 1966

Authors and Affiliations

  • Laszlo Gyermek

There are no affiliations available

Personalised recommendations